| Bioactivity | CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysis[1]. |
| Target | NRF2 |
| Invitro | CBR-470-2 (1-10 μM; 24 h) increases transcript levels of the NRF2-responsive genes NQO1 and HMOX1 in epidermal keratinocytes and dermal fibroblasts[1]. |
| In Vivo | CBR-470-2 (50 mg/kg; p.o. twice daily for 10 d) induces activation of NRF2 signaling in vivo[1]. Animal Model: |
| Name | CBR-470-2 |
| CAS | 2416095-00-4 |
| Formula | C12H13Cl2NO6S2 |
| Molar Mass | 402.27 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
| Reference | [1]. Bollong MJ, et, al. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature. 2018 Oct;562(7728):600-604. |
CBR-470-2
CAS: 2416095-00-4 F: C12H13Cl2NO6S2 W: 402.27
CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulati
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.